Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for ta621

  1. Past appeals and decisions

    Past technology appraisal appeals and decisions

  2. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Withdrawn guidance